Atlas Trials

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Clinical trial NCT03628209 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03628209
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
OsteosarcomaOsteosarcoma in ChildrenOsteosarcoma RecurrentSarcoma
Start date
2019-10-03
Primary completion
2024-12-29
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.